Who makes varespladib-methyl- oral form?

varespladib-methyl- oral form is developed by Ophirex, Inc..

What development phase is varespladib-methyl- oral form in?

varespladib-methyl- oral form is in Phase 2.

Last reviewed 2026-04-19 · How we verify

varespladib-methyl- oral form

Ophirex, Inc. · Phase 2 active Small molecule

At a glance

Generic name	varespladib-methyl- oral form
Also known as	LY333013
Sponsor	Ophirex, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

varespladib-methyl- oral form CI brief — competitive landscape report
varespladib-methyl- oral form updates RSS · CI watch RSS
Ophirex, Inc. portfolio CI